Supreme Court Upholds Medicare Drug Price Negotiation Program, Impacting Big Pharma

The U.S. Supreme Court has dismissed appeals from major pharmaceutical companies contesting a Medicare program that allows for the negotiation of drug prices, a move expected to save billions for taxpayers and the federal government. This decision maintains lower court rulings that support the program established by the 2022 Inflation Reduction Act, which aims to alleviate the financial burden of rising prescription drug costs on Medicare beneficiaries. The first round of negotiations has already led to significant savings, with projections of $6 billion in federal savings and $1.5 billion in reduced out-of-pocket costs for seniors. Ongoing legal challenges from drugmakers argue that the program violates their rights, but courts have consistently ruled that participation in Medicare is voluntary.

Key Details: • First round of negotiations involved 10 drugs, effective January 2024. • Projected savings include $6 billion for Medicare and $1.5 billion for seniors. • Second round covers 15 drugs, expected to save $12 billion and reduce costs by $685 million. • Drugmakers can withdraw from Medicare if they disagree with negotiated prices.